Incretin-based therapy: renal effects
Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic ki...
Saved in:
Main Authors: | Anton Ivanovich Korbut, Vadim Valerievich Klimontov |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/5c2fe686f9b64d1a9647f4b4cad14b69 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016) -
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019) -
Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019) -
New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011) -
Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011)